

# Processing Speed Impairment in Schizophrenia

## An Updated Systematic Review and Meta-Analysis

Danielle N. Pratt, PhD; Nashya Linares, BA; Catherine Spencer, MA; Gabrielle M. Olson, BA; Maeve Hoffman, BA; Sophia Parmacek, MS; Lauren E. Lee, BS; Luz Maria Allende, MA; Vanessa Zarubin, MS; Dwight Dickinson, PhD; James M. Gold, PhD; Vijay A. Mittal, PhD

[+ Supplemental content](#)

**IMPORTANCE** Cognition is impaired in people with schizophrenia, affecting quality of life and functioning. Therefore, it is important to understand and characterize this impairment.

**OBJECTIVE** To update and revisit the evidence for a central processing speed impairment in people with schizophrenia and examine the factors that moderate this impairment.

**DATA SOURCES** Articles were identified through the PubMed and PsycINFO databases from February 1, 2009, through November 2, 2023.

**STUDY SELECTION** Studies were included if they reported on a symbol coding test and at least 2 additional cognitive tests from 2 other cognitive domains, contrasted people with schizophrenia to controls, used contemporary diagnostic criteria, included sufficient detail to calculate Hedges  $g$  effect sizes, and were reported in English. Of 4530 identified articles, 115 studies met inclusion criteria.

**DATA EXTRACTION AND SYNTHESIS** This study followed the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines. Means, SDs, and sample sizes were extracted for all cognitive tests that appeared in at least 3 of the 115 studies. Data were entered and visually checked by independent extractors. Data were generally pooled using random-effects models, except when specified. Measures of homogeneity ( $Q$  and  $I^2$ ) and publication bias (fail-safe  $N$  and funnel plots) were also examined.

**MAIN OUTCOMES AND MEASURES** The primary outcome was the degree of cognitive impairment (Hedges  $g$ ) observed for people with schizophrenia in 50 cognitive tests, focusing on symbol coding tests of processing speed. Further, this study aimed to identify clinical and study characteristics that moderate the degree of symbol coding impairment.

**RESULTS** Data were available for 10 114 people with schizophrenia and 13 235 controls from 115 studies. Symbol coding tasks were among the most impaired ( $g = -1.52$ ; 95% CI,  $-1.65$  to  $-1.40$ ) but did not reliably differ from 15 other tests. Intelligence quotient and age difference from controls, composition of sex assigned at birth, inpatient status, and whether the sample included schizoaffective and schizophreniform diagnoses all moderated the degree of symbol coding impairment.

**CONCLUSIONS AND RELEVANCE** This meta-analysis provides insight into the consistency of the processing speed impairment for people with schizophrenia. Findings support that this impairment may be central to global cognitive impairments, which might be a consequence of altered brain connectivity.

**Author Affiliations:** Department of Psychology, Northwestern University, Evanston, Illinois (Pratt, Linares, Spencer, Olson, Hoffman, Parmacek, Lee, Allende, Zarubin, Mittal); Clinical and Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland (Dickinson); Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore (Gold); Department of Psychiatry, Northwestern University, Chicago, Illinois (Mittal); Institute for Policy Research, Northwestern University, Chicago, Illinois (Mittal); Institute for Adolescent Mental Health and Well-Being, Northwestern University, Evanston, Illinois (Mittal).

**Corresponding Author:** Danielle N. Pratt, PhD, Northwestern University, 1801 Maple Ave, Ste 3120, Evanston, IL 60201 ([danielle.pratt@northwestern.edu](mailto:danielle.pratt@northwestern.edu)).

JAMA Psychiatry. doi:10.1001/jamapsychiatry.2025.3893  
Published online December 23, 2025.

People with schizophrenia often experience cognitive impairments that are about 1 SD below their peers without a psychiatric diagnosis.<sup>1-3</sup> These cognitive impairments significantly affect quality of life<sup>4-6</sup> and impact both social<sup>7,8</sup> and role<sup>9,10</sup> functional capacity. Processing speed has repeatedly emerged as particularly impaired in this population, especially when measured by using digit symbol coding tests.<sup>1,2,11</sup> However, there have been significant changes to the underlying literature since this topic was last examined, such as greater representation of research from around the world, larger datasets, and novel or updated cognitive tests. Additionally, there is conflicting literature on whether first-generation antipsychotics, which have been prescribed less over time,<sup>12</sup> cause motor impairment and thus might explain the degree of processing speed impairment previously observed. Therefore, it is vital to assess the robustness of this finding in recent literature and further examine the potential factors contributing to this large impairment.

Processing speed is the speed at which cognitive operations can be executed.<sup>2,13,14</sup> Assessments of processing speed are typically speed tests, or tests that require individuals to complete as much as they can in a short amount of time of a task designed so that nearly anyone can complete any given item, compared to power tests that are intended to increase in difficulty and measure the extent of one's abilities in a given domain.<sup>15,16</sup> For example, digit symbol coding (henceforth, symbol coding) tests require participants to use a key—featuring the numbers 1 through 9 each paired with a unique symbol—to match a long and random series of either the symbols to the numbers<sup>17</sup> or the numbers to the symbols<sup>18</sup> as fast as they can without skipping any. Relative to the global cognitive impairment, people with schizophrenia demonstrate greater impairment on symbol coding tests, with meta-analytic estimates of performance being approximately 1.5 SDs below controls.<sup>2,11</sup> Since this finding, symbol coding tests have played an important role in psychosis research, including contributing to estimates of the risk an individual has of developing a psychotic disorder.<sup>19</sup>

According to Dickinson and colleagues,<sup>2</sup> the global cognitive impairment observed in people with schizophrenia may be the consequence of a central processing speed impairment. As processing speed is a lower-order cognitive operation, it may be necessary for performing many higher-order operations (eg, encoding and retrieval, information transformation, and decision-making), which are often measured with speed-dependent assessments.<sup>2,20</sup> Alternatively, processing speed may be particularly sensitive to altered brain connectivity, which may in turn be the mechanism driving broad cognitive impairment in people with schizophrenia.<sup>2,21</sup> However, connectivity and processing speed are only moderately associated,<sup>22</sup> and altered connectivity likely only partially explains the specific processing speed deficit, leaving much to be understood about cognitive impairment in this population.

Since the formative meta-analysis by Dickinson et al<sup>2</sup> identifying symbol coding tasks as the most impaired cognitive test for people with schizophrenia, there have been numerous changes to the clinical and research landscape. Therefore, the

## Key Points

**Question** Is there continued evidence of a central processing speed deficit for people with schizophrenia?

**Findings** In this systematic review and meta-analysis of 115 studies, symbol coding tests of processing speed remained among the most impaired cognitive tests for people with schizophrenia. Of the 49 other cognitive tests examined, symbol coding was reliably more impaired than 34 of them.

**Meaning** This study suggests that processing speed continues to emerge as a particularly impaired cognitive domain, and findings indicate there may be an underlying mechanism driving global cognitive impairment, such as altered brain connectivity, that processing speed is especially sensitive to.

primary aim of this study is to replicate and update this meta-analysis by examining the impairment observed for symbol coding tests compared with other cognitive tests in people with schizophrenia. We hypothesize that symbol coding tasks will continue to emerge as particularly impaired. Following previous work by Knowles et al,<sup>11</sup> this study further aims to explore potential variables that may moderate symbol coding impairment, including clinical indicators (eg, antipsychotic medication dose and age at illness onset) and study characteristics (eg, publication date and participant age).


## Methods

This meta-analysis was preregistered with the Open Science Framework. We followed the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines.

### Study Selection and Inclusion

Articles were identified through the PubMed and PsycINFO databases with combinations of the key words *schizophreni\**, *cogniti\**, *neuropsychologi\**, *digit symbol*, *symbol coding*, *processing speed*, *perceptual speed*, and *psychomotor speed* from February 1, 2009, through November 2, 2023. Studies were included if they (1) reported on a written symbol coding task, (2) featured at least 2 additional cognitive assessments from at least 2 different cognitive domains, (3) contrasted a group of people with schizophrenia (schizoaffective and schizophreniform disorders permitted) with healthy controls, (4) used contemporary diagnostic criteria (eg, *DSM-IV*, *DSM-5*, or *International Classification of Diseases, Ninth Revision* or later version), (5) reported sufficient detail to calculate effect sizes, and (6) were reported in English (Figure 1; eTable 1 in Supplement 1).<sup>23-137</sup>

Means, SDs, and sample sizes for a written symbol coding test were recorded for all studies by 9 trained extractors and visually checked by an independent extractor. The same metrics were tracked for all cognitive tests that appeared in at least 3 of the included studies. Ultimately, 50 different cognitive tests from 10 cognitive domains were meta-analyzed. Individual tests were generally assessed separately; however, similar tests

**Figure 1. PRISMA Diagram of Study Identification, Screening, and Inclusion**

After removing 2876 duplicate records, 1654 articles were screened for inclusion. A total of 190 articles were sought for retrieval and 115 studies were included in this meta-analysis.

(eg, various word list-learning tests<sup>138-140</sup>) were combined for simplicity (eTable 2 in Supplement 1). Information on potential moderator variables was also recorded when available, including clinical variables on the severity and chronicity of illness, presence and dosage of antipsychotic medication, and study characteristics (eg, age, education, sex assigned at birth, race, and publication date). When reported data were unclear or appeared incorrect, efforts were made to contact the study's authors.

### Data Analysis

A detailed description of the analytical plan is in the eMethods in Supplement 1. Analyses were performed using R, version 4.2.2 (R Project for Statistical Computing)<sup>141</sup> using the metafor<sup>142</sup> package. Most cognitive tests were reported so that higher scores reflect better performance. When higher scores reflected worse performance (eg, time to complete a task), the signs of the raw scores were reversed to aid in interpretation. All *P* values reported are 2-sided, with the statistical significance threshold set to *P* < .05.

To estimate the degree of impairment observed for each of the 50 cognitive tests, separate random-effects meta-analyses were run to calculate Hedges *g* effect sizes.<sup>143</sup> Mea-

sures of homogeneity (*Q* and *I*<sup>2</sup>)<sup>144,145</sup> and publication bias (fail-safe *N*<sup>146</sup> and funnel plots) were also examined. Global cognitive and cognitive domain effect sizes were calculated via multivariate meta-analyses specifying cognitive tests nested within studies as a random effect to account for studies with multiple tests in the same domain. To directly compare whether symbol coding impairment differed from the other cognitive tests, subgroups of studies that included both symbol coding and the comparator cognitive tests were re-examined.<sup>2,147</sup> Specifically, multivariate meta-analyses with cognitive test (symbol coding vs comparator variable) as a moderator variable were conducted. Additionally, the results of this study were compared to the results reported in Dickinson et al<sup>2</sup> using fixed-effects meta-analyses specifying study (Pratt vs Dickinson) as a moderator variable. Further, a 2-way, average measures intraclass correlation (ICC) with absolute agreement was calculated for cognitive tests with at least 8 individual studies in each meta-analysis. Lastly, the effect of clinical and study moderator variables on symbol coding performance was examined using random-effects meta-regressions.

### Results

A total of 115 studies met the inclusion criteria<sup>23-137</sup>; cognitive data were analyzed for 10 114 people with schizophrenia and 13 235 controls across these studies (eTable 1 in Supplement 1). For studies that report age, the sample-weighted mean (SD) age of the participants with schizophrenia was 36.98 (9.03) years (range, 15.79-63.50 years; number of studies [*k*] = 112) and 38.26 (9.88) years (range, 15.42-63.46 years; *k* = 110) for controls. Consistent with prior findings, people with schizophrenia exhibited a large global cognitive impairment relative to controls (*g* = −1.12; 95% CI, −1.21 to −1.03).


### Symbol Coding Meta-Analysis

The random-effects meta-analysis on symbol coding impairment yielded a large effect size (*g* = −1.52; 95% CI, −1.65 to −1.40; *k* = 115), similar to prior meta-analyses (*g* = −1.57<sup>2</sup> and *g* = −1.50<sup>11</sup>). This finding indicates more than a 70% nonoverlap between people with schizophrenia and controls.<sup>148</sup> The fail-safe *N* indicated that 734 studies with null effects would have to be published to reduce the effect size to −0.2, and 14 431 null studies to reduce it to a nonsignificant finding. There was a large amount of heterogeneity among studies (*I*<sup>2</sup> = 93.94%; *Q*<sub>114</sub> = 1441.72; *P* < .001). Most studies are grouped around the overall effect, but many do not fall within the 95% CI (eFigure 1A in Supplement 1). Only 3 studies<sup>37,63,125</sup> did not find significant impairment relative to controls, and much of the variability comes from studies with quite large effect sizes (*g* range, −4.86 to −0.03) (eFigure 1B in Supplement 1).

### Meta-Analyses of Other Cognitive Tests

Each individual cognitive test, as well as domain, was significantly impaired relative to controls (Figure 2; eTable 3 in Supplement 1). Effect sizes ranged from *g* = −0.53 (information) to *g* = −1.64 (Stroop-word reading). In contrast to previous meta-analyses, 2 other processing speed tests (Stroop-

Figure 2. Meta-Analytic Effect Size by Cognitive Tests and Domains



word reading and symbol search) had similar, but greater, impairments than symbol coding tests. Funnel and forest plots for each meta-analysis can be found in eFigures 1-50 in [Supplement 1](#).

### Matched Comparisons

Symbol coding impairment was reexamined in subsets of studies that include each comparator cognitive test, so tests could be compared with approximately equal sample sizes. All matched comparisons revealed that symbol coding exhibited greater impairment. However, the difference was not significant for 15 of the 49 comparator cognitive tests, and therefore, it cannot be concluded that symbol coding is reliably more impaired for people with schizophrenia on these tests ([Table 1](#)). These 15 tests were spread across all domains except for perceptual reasoning. Nearly half of these were tests of processing speed (3 of 4) and learning and memory (4 of 10).

### Comparison With Previous Meta-Analysis Findings

To compare our findings with those in Dickinson et al,<sup>2</sup> effect sizes were compared for the 27 cognitive tests included in both meta-analyses ([Table 2](#)). Of these tests, only 5 of them differed significantly across studies: Stroop-word reading, category fluency, visual memory-delayed, information, and vocabulary. An ICC between cognitive tests that appeared in at least 8 studies in both meta-analyses revealed good agreement in the level of cognitive impairment observed (ICC = 0.814; 95% CI, 0.50-0.93).

### Examination of Moderator Variables

As in Knowles et al,<sup>11</sup> the larger the difference in intelligence quotient (IQ) between people with schizophrenia and controls within a study, the larger the symbol coding impairment was ( $g = -0.02$ ; 95% CI,  $-0.03$  to  $-0.00$ ;  $P = .009$ ) ([Figure 3A](#)). However, unlike previous findings, there was no association of chlorpromazine equivalent ( $g = 0.00$ ; 95% CI,  $-0.001$  to  $0.001$ ;  $P = .53$ ) or publication date ( $g = -0.03$ ; 95% CI,  $-0.06$  to  $0.02$ ;  $P = .06$ ) with symbol coding performance.

Two additional study characteristics moderated the degree of symbol coding impairment for people with schizophrenia. First, we found that the difference in mean age between the schizophrenia and control groups within a study moderated the observed impairment; the older the people with schizophrenia were relative to the controls in a study, the larger the observed symbol coding impairment and vice versa ( $g = 0.06$ ; 95% CI,  $0.02$ - $0.09$ ;  $P = .001$ ) ([Figure 3B](#)). Without considering the age of the control group, age of the schizophrenia group was not a significant moderator. Second, we found that as the percentage of females assigned at birth within a group of people with schizophrenia increases, the observed symbol coding impairment gets larger ( $g = 0.01$ ; 95% CI,  $-0.02$  to  $-0.00$ ;  $P = .02$ ) ([Figure 3C](#)). Neither the level of education among people with schizophrenia nor the difference in education between the control and schizophrenia groups moderated the symbol coding effect. There may be greater impairment observed in studies conducted in Asia (eFigure 51 in [Supplement 1](#)), but race was not a significant moderator. Notably, symbol coding impairment did not differ by test ver-

sion used, except that the symbol coding test from the Brief Assessment of Cognition in Schizophrenia measured greater impairment than the Wechsler Adult Intelligence Scale coding version ( $g = -0.29$ ; 95% CI,  $-0.57$  to  $-0.01$ ;  $P = .04$ ).

Two clinical variables moderated the degree of symbol coding impairment in people with schizophrenia. Inpatients with schizophrenia showed more impairment on symbol coding tests compared with outpatients and mixed groups ( $g = -0.42$ ; 95% CI,  $-0.77$  to  $-0.08$ ;  $P = .02$ ) ([Figure 3D](#)). Further, groups that included people with schizoaffective disorder and/or schizophreniform disorder were less impaired than those with schizophrenia only ( $g = 0.46$ ; 95% CI,  $0.17$ - $0.75$ ;  $P = .002$ ) ([Figure 3E](#)). Surprisingly, whether the participants were currently receiving medication, were drug-naïve, were in a first episode, had an early onset of illness, or were in an acute or remitted phase of illness did not moderate the level of symbol coding impairment. Similarly, neither the duration of untreated psychosis nor age at psychosis onset moderated performance.

## Discussion

In this meta-analysis, we examined the degree of cognitive impairment experienced by people with schizophrenia across 50 frequently used cognitive measures. Previous meta-analyses have found that symbol coding tests of processing speed are the most impaired cognitive measure for people with schizophrenia. Thus, 115 studies with a symbol coding test and at least 2 additional tests from 2 different cognitive domains were included in this study. We found that the level of impairment seen on symbol coding tests has remained consistent across meta-analyses, but that this impairment may not be uniquely greater than for all other cognitive tests. Additionally, several study and clinical characteristics were found to moderate the degree of symbol coding impairment.

In this study, symbol coding tests remained among the most impaired cognitive tests for people with schizophrenia, but the findings were nuanced. Across all included studies, Stroop-word reading and symbol search had larger overall effect sizes than symbol coding. However, these tests were featured in considerably fewer studies and when compared in matched samples, symbol coding was more impaired, although not significantly. Notably, these are all tests of processing speed, supporting that this domain is a particularly impaired for people with schizophrenia. However, they are also very different tasks with distinct cognitive demands, indicating that the underlying cause of impairment is not specific to symbol coding. In fact, in matched comparisons, symbol coding impairment did not significantly differ from the impairment observed in 15 of the 49 cognitive tests spanning all cognitive domains except perceptual reasoning. Of these 15 tests, only 6 are particularly speed dependent, and there is no clear cognitive operation that is common and unique to these tests. However, some caution is warranted while interpreting these nonsignificant findings; 6 of these 15 tests were not well represented in the literature ( $\leq 6$  studies), and there were still notable differences in effect size magnitude for all tests aside from symbol search and mazes (9 tests



Table 1. Matched Comparisons with Symbol Coding Tests

Cognitive domain or measure	k	No. of participants		Effect size (SE)		z value	P value
		Schizophrenia	Control	Test	SC		
Processing speed							
Symbol search	9	1228	4001	-1.59 (0.14)	-1.65 (0.19)	0.260	.80
Trails A <sup>a</sup>	48	4422	4911	-1.03 (0.06)	-1.52 (0.11)	12.76	<.001
Stroop-color naming	8	495	1096	-1.44 (0.19)	-1.75 (0.34)	1.73	.08
Stroop-word reading	8	493	1104	-1.64 (0.24)	-2.02 (0.37)	1.41	.16
Verbal fluency							
Category fluency <sup>a</sup>	46	4166	5463	-1.07 (0.10)	-1.62 (0.13)	3.33	.001
Phonemic fluency	28	1928	3315	-1.16 (0.23)	-1.57 (0.12)	1.58	.11
Verbal fluency combined <sup>a</sup>	13	1206	1137	-1.26 (0.10)	-1.69 (0.12)	2.76	.006
Learning and memory							
Verbal learning-immediate <sup>a</sup>	64	6654	7737	-1.29 (0.08)	-1.60 (0.10)	2.42	.02
Verbal learning-delayed <sup>a</sup>	18	1787	1853	-1.08 (0.08)	-1.57 (0.11)	3.60	<.001
Verbal learning-recognition	4	98	158	-1.09 (0.24)	-2.14 (0.50)	1.91	.06
Visual memory-immediate <sup>a</sup>	21	2675	4270	-1.10 (0.13)	-1.61 (0.22)	2.03	.04
Visual memory-delayed	4	706	2366	-1.49 (0.21)	-1.92 (0.22)	1.41	.16
Rey-O-immediate	4	177	303	-0.82 (0.30)	-1.68 (0.37)	1.80	.07
Story memory-immediate	12	1174	3021	-1.23 (0.10)	-1.52 (0.12)	1.80	.07
Story memory-delayed <sup>a</sup>	10	1085	2950	-1.27 (0.11)	-1.62 (0.10)	2.24	.03
Verbal paired associates-immediate <sup>a</sup>	3	715	2528	-1.03 (0.14)	-1.75 (0.06)	4.65	<.001
Verbal paired associates-delayed <sup>a</sup>	3	712	2527	-0.88 (0.08)	-1.75 (0.06)	8.53	<.001
Working memory							
Arithmetic <sup>a</sup>	17	2029	4565	-0.94 (0.12)	-1.30 (0.13)	1.98	.05
Digit span forward <sup>a</sup>	15	1385	1975	-0.75 (0.07)	-1.69 (0.20)	4.36	<.001
Digit span backward <sup>a</sup>	15	1359	2085	-0.78 (0.06)	-1.58 (0.17)	4.37	<.001
Digit span sequencing <sup>a</sup>	19	1620	1507	-1.27 (0.15)	-1.83 (0.17)	2.42	.02
Digit span combined <sup>a</sup>	19	1642	4434	-0.68 (0.08)	-1.46 (0.14)	4.89	<.001
Letter number sequencing <sup>a</sup>	34	2751	5360	-0.95 (0.05)	-1.47 (0.08)	5.64	<.001
Consonant repetition test	4	219	203	-0.89 (0.20)	-1.26 (0.21)	1.27	.20
Spatial span forward <sup>a</sup>	5	572	409	-0.70 (0.07)	-1.80 (0.30)	3.63	<.001
Spatial span backward <sup>a</sup>	4	359	286	-0.86 (0.09)	-1.80 (0.40)	2.31	.02
Spatial span combined <sup>a</sup>	21	1851	2382	-0.92 (0.08)	-1.62 (0.22)	3.07	.002
Executive functioning							
Mazes	16	1901	1732	-1.34 (0.19)	-1.50 (0.26)	0.52	.60
Stroop-C-W interference <sup>a</sup>	14	1005	2112	-1.25 (0.16)	-1.78 (0.20)	3.14	.002
Stroop-switching <sup>a</sup>	3	226	404	-0.91 (0.09)	-1.41 (0.09)	17.87	<.001
Tower of London <sup>a</sup>	20	1651	1509	-0.94 (0.15)	-1.88 (0.17)	4.10	<.001
Trails B <sup>a</sup>	25	1504	2692	-1.04 (0.07)	-1.52 (0.08)	13.43	<.001
WCST-errors <sup>a</sup>	4	379	1251	-0.89 (0.06)	-1.59 (0.14)	16.32	<.001
WCST-No. of categories	6	545	1341	-0.99 (0.06)	-1.34 (0.28)	1.25	.21
WCST-perseverative errors <sup>a</sup>	9	668	1464	-0.90 (0.10)	-1.43 (0.19)	6.09	<.001
Attention							
CPT-IP	14	1507	1513	-1.14 (0.20)	-1.73 (0.33)	1.54	.12
CPT <sup>a</sup>	3	395	427	-1.15 (0.10)	-1.52 (0.09)	2.70	.007
Motor							
Token motor	16	1424	1362	-1.39 (0.13)	-1.69 (0.09)	1.87	.06
Perceptual reasoning							
Block design <sup>a</sup>	17	2173	4986	-0.69 (0.08)	-1.27 (0.12)	3.93	<.001
Matrix reasoning <sup>a</sup>	10	1371	4342	-0.87 (0.12)	-1.48 (0.12)	3.54	<.001
Picture arrangement <sup>a</sup>	8	1444	3847	-0.85 (0.09)	-1.61 (0.11)	5.30	<.001
Picture completion <sup>a</sup>	12	1330	4141	-0.91 (0.05)	-1.64 (0.14)	4.79	<.001

(continued)

Table 1. Matched Comparisons with Symbol Coding Tests (continued)

Cognitive domain or measure	k	No. of participants		Effect size (SE)		z value	P value
		Schizophrenia	Control	Test	SC		
Verbal comprehension							
Comprehension	11	1314	4188	−1.23 (0.16)	−1.49 (0.11)	1.35	.18
Information <sup>a</sup>	18	2083	4601	−0.53 (0.09)	−1.30 (0.12)	5.07	<.001
Similarities <sup>a</sup>	16	1877	4685	−0.74 (0.11)	−1.50 (0.09)	5.32	<.001
Vocabulary <sup>a</sup>	22	2818	5690	−0.79 (0.08)	−1.45 (0.08)	6.01	<.001
Social cognition							
Emotion recognition <sup>a</sup>	6	614	891	−0.72 (0.14)	−1.43 (0.30)	2.13	.03
MSCEIT <sup>a</sup>	10	1446	1272	−0.56 (0.11)	−1.46 (0.22)	3.70	<.001
Reading the Mind in the Eyes	4	392	561	−0.65 (0.15)	−1.15 (0.25)	1.71	.09

Abbreviations: CPT, Continuous Performance Test; CPT-IP, Continuous Performance Test-Identical Pairs; C-W, color-word; k, number of studies; MSCEIT, Mayer-Salovey-Caruso Emotional Intelligence Test; SC, subsetted

symbol coding; Test, comparator test; WCST, Wisconsin Card Sorting Test.

<sup>a</sup>  $P < .05$ .


Table 2. Comparing Effect Sizes of Cognitive Tests Across Studies

Cognitive domain or measure	Effect size (SE)		z value	P value
	Dickinson	Pratt		
Processing speed				
Symbol coding	−1.57 (0.05)	−1.52 (0.07)	0.58	.56
Trails A	−0.88 (0.07)	−1.03 (0.07)	−1.52	.13
Stroop-word reading <sup>a</sup>	−0.97 (0.15)	−1.64 (0.24)	−2.37	.02
Verbal fluency				
Category fluency <sup>a</sup>	−1.41 (0.11)	−1.07 (0.10)	2.29	.02
Phonemic fluency	−0.83 (0.06)	−1.16 (0.23)	−1.39	.16
Learning and memory				
Verbal learning-immediate	−1.25 (0.10)	−1.29 (0.08)	−0.31	.76
Verbal learning-delayed	−1.09 (0.08)	−1.08 (0.08)	0.09	.93
Visual memory-immediate	−0.82 (0.10)	−1.10 (0.13)	−1.71	.09
Visual memory-delayed <sup>a</sup>	−0.78 (0.09)	−1.49 (0.21)	−3.11	.002
Rey-O-immediate	−1.03 (0.13)	−0.82 (0.30)	0.64	.52
Story memory-immediate	−1.19 (0.11)	−1.23 (0.10)	−0.27	.79
Story memory-delayed	−1.29 (0.11)	−1.27 (0.11)	0.13	.90
Verbal paired associates-immediate	−1.12 (0.26)	−1.03 (0.14)	0.31	.76
Working memory				
Arithmetic	−1.18 (0.10)	−0.94 (0.12)	1.54	.12
Digit span forward	−0.87 (0.15)	−0.75 (0.07)	0.73	.47
Digit span backward	−0.86 (0.14)	−0.78 (0.06)	0.53	.60
Digit span combined	−0.71 (0.06)	−0.68 (0.08)	0.30	.76
Letter number sequencing	−0.85 (0.11)	−0.95 (0.05)	−0.83	.41
Executive functioning				
Stroop-C-W interference	−0.99 (0.14)	−1.25 (0.16)	−1.22	.22
Trails B	−0.99 (0.06)	−1.04 (0.07)	−0.54	.59
WCST-No. of categories	−1.00 (0.10)	−0.99 (0.07)	−0.08	.93
WCST-perseverative errors	−0.81 (0.07)	−0.90 (0.10)	−0.74	.46
Attention				
CPT-IP	−0.86 (0.14)	−1.14 (0.20)	−1.15	.25
Perceptual reasoning				
Block design	−0.84 (0.12)	−0.69 (0.08)	1.04	.30
Verbal comprehension				
Information <sup>a</sup>	−0.82 (0.10)	−0.53 (0.09)	2.16	.03
Similarities	−0.90 (0.11)	−0.74 (0.11)	1.03	.30
Vocabulary <sup>a</sup>	−1.08 (0.10)	−0.79 (0.08)	2.27	.02

Abbreviations: CPT-IP, Continuous Performance Test-Identical Pairs; C-W, color-word; WCST, Wisconsin Card Sorting Test.

<sup>a</sup>  $P < .05$ .

Figure 3. Meta-Regressions of Significant Study Variables



The point size corresponds to the square root of the inverse of the SE. A, The IQ difference between groups; the lower the IQ among people in the schizophrenia group compared with those in the control group, the larger the effect size. B, The age difference between groups; the younger the age among people in the schizophrenia group is compared with those in the control group, the smaller the effect size. C, Percentage of females assigned at birth; the more females

assigned at birth in the group, the larger the impairment. D, Inpatient status of people in the schizophrenia group; inpatient groups were more impaired than outpatient or mixed groups. E, Presence of participants with schizoaffective and/or schizophreniform disorder; groups that were mixed were less impaired than schizophrenia-only groups. IQ indicates intelligence quotient.

had small effect size differences of  $\Delta g = 0.2-0.49$ , 2 had medium differences of  $\Delta g = 0.5-0.8$ , and 2 had large differences of  $\Delta g > 0.8$ ). Therefore, it may not be that symbol coding tests measure a specific cognitive ability that is more impaired than other abilities, but rather that it is a good measure of an underlying impairment that variably influences other cognitive operations. This finding may be consistent with the altered brain connectivity hypothesis of processing speed,<sup>104</sup> and general cognitive,<sup>149</sup> impairment.

The cognitive impairment profile for people with schizophrenia has remained largely consistent across examinations, despite evolving research methods and novel clinical treatments. Previous meta-analyses found a global cognitive impairment of approximately 1 SD,<sup>1,2</sup> which is replicated presently. Although samples were nonoverlapping and from different periods (1990-2006 vs 2010-2023), there was good agreement in the pattern of cognitive impairment observed with Dickinson et al.<sup>2</sup> Of the 27 cognitive tests featured in both

studies, the effect sizes of 22 of them did not significantly differ. Five cognitive tests revealed significantly different effect sizes over time, but it was not a uniform shift; 3 tests were observed to be less impaired in the present study, while 2 were observed to be more impaired. The differing tests were spread across different domains and do not have any clear qualities in common, making these differences difficult to interpret and likely the result of measurement error and expected sampling variation.

Several factors affect the degree of symbol coding impairment observed within a study. Three study characteristics significantly moderated the symbol coding effect. First, we found that the difference in IQ between the schizophrenia and control groups within a study affected the degree of symbol coding impairment observed. This finding is consistent with Knowles et al<sup>11</sup> and logical given that IQ is a measure of general cognitive ability and may even include a symbol coding task as part of the calculation. Second, we found that the dif-



ference in age between the groups within a study moderated the symbol coding impairment, which is consistent with the literature that processing speed slows as individuals age<sup>150</sup>; the younger the schizophrenia group is relative to the control group, the less impairment is observed. Interestingly, the mean age of the schizophrenia groups alone did not moderate the degree of impairment observed, indicating that the relative impairment is stable across the postdiagnosis lifespan, and processing speed might slow at a similar rate to controls. Third, we found that as the percentage of females assigned at birth among the schizophrenia groups increased, symbol coding performance was more impaired. This finding is rather confounding because females assigned at birth are typically observed to outperform males assigned at birth on symbol coding tests.<sup>151-153</sup> Therefore, future examination of this effect is warranted. Two clinical characteristics also moderated the degree of symbol coding impairment, including whether it was an inpatient group and whether the group included people with schizoaffective or schizophreniform disorders. These findings are also in line with the greater literature, where inpatient groups often show greater impairment than outpatient groups,<sup>154</sup> and people with other psychotic disorders show attenuated cognitive impairment relative to those with schizophrenia.<sup>155</sup>

### Limitations

This study had several limitations. First, for parsimony and feasibility, similar tests were assessed together, as has been done previously.<sup>1,2</sup> It is unlikely that small methodological differences in test versions would fundamentally change the observed impairment, but it is possible. Second, while 115 studies were examined, this is only a fraction of studies on cognition in people with schizophrenia. Although our results are consistent with the literature and the matched comparison findings are encouraging, it is likely that effect sizes would differ

marginally had the search criteria not been centered on symbol coding. Third, there was limited representation of cognitive domains such as reward and motivation in the included studies, and future research is needed to compare impairment in these domains with processing speed. Fourth, the results indicate considerable heterogeneity in the measurement of cognitive functions. We expected this heterogeneity because schizophrenia is a heterogeneous disorder, cognitive testing is psychometrically limited,<sup>156</sup> study methodology varies, and the effect of moderator variables on processing speed performance. However, some of this heterogeneity may be due to publication bias, highlighting the need to publish null findings, focus efforts on collecting sufficient sample sizes, and use careful methodology. Given that cognitive operations work in parallel, future research should examine how processing speed interacts with other cognitive abilities to either produce or avoid cognitive deficits. Additionally, although processing speed abilities can be ascertained quickly and easily, it is not clear that performance is firmly linked to any 1 brain system; therefore, its utility as a biomarker must be further examined.

### Conclusion

In this meta-analysis, we found that despite evolving research methods and clinical interventions and better inclusion of research from understudied parts of the world, processing speed continues to emerge as particularly impaired for people with schizophrenia. Specifically, symbol coding tests reliably measured the full extent of cognitive impairment in people with schizophrenia. This work added to the substantial evidence that slowed information processing is a central feature of the cognitive impairment seen in schizophrenia, which is potentially a reflection of the altered brain connectivity in this population.

### ARTICLE INFORMATION

**Accepted for Publication:** October 1, 2025.

**Published Online:** December 23, 2025.  
doi:10.1001/jamapsychiatry.2025.3893

**Author Contributions:** Dr Pratt had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Pratt, Dickinson, Mittal.

**Acquisition, analysis, or interpretation of data:** Pratt, Linares, Spencer, Olson, Hoffman, Parmacek, Lee, Allende, Zarubin, Gold, Mittal.

**Drafting of the manuscript:** Pratt, Mittal.

**Critical review of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Pratt, Dickinson, Mittal.

**Obtained funding:** Pratt, Mittal.

**Administrative, technical, or material support:** Linares, Spencer, Olson, Hoffman, Parmacek, Lee, Allende, Mittal.

**Supervision:** Dickinson, Mittal.

**Conflict of Interest Disclosures:** Dr Pratt, Ms Zarubin, and Dr Mittal reported receiving grants from National Institute of Mental Health during the conduct of the study. Dr Pratt reported receiving personal fees from Click Therapeutics for consulting

outside the submitted work. No other disclosures were reported.

**Funding/Support:** This work was funded by National Institute of Mental Health grants awarded to Dr Pratt (grant 1F32MH139246-01), Ms Zarubin (grant F31MH139284), and Dr Mittal (grants NIMH-R01MH136185 and 1R01MH120088-01A).

**Role of the Funder/Sponsor:** The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement:** See [Supplement 2](#).

### REFERENCES

- Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. *Schizophr Res*. 2013;150(1):42-50. doi:10.1016/j.schres.2013.07.009
- Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. *Arch Gen Psychiatry*. 2007;64(5):532-542. doi:10.1001/archpsyc.64.5.532
- Cruz BF, Resende CB, Carvalhaes CF, et al. Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms. *Braz J Psychiatry*. 2016;38(3):216-221. doi:10.1590/1516-4446-2015-1776
- Lin C, Wan X, Zhang R, Yang X, Liu Y. Quality of life and its influencing factors in patients with schizophrenia. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. 2023;48(3):472-480.
- Ojeda N, Sánchez P, Peña J, et al. An explanatory model of quality of life in schizophrenia: the role of processing speed and negative symptoms. *Actas Esp Psiquiatr*. 2012;40(1):10-18.
- Mwesiga EK, Ssemata AS, Gumikiriza J, et al. The association of cognitive impairment with quality of life and functional impairment in Ugandan first-episode psychosis patients: a cross sectional study. *Health Qual Life Outcomes*. 2022;20(1):113. doi:10.1186/s12955-022-02020-x
- Abella M, Vila-Badia R, Serra-Arumí C, et al. The relevance of processing speed in the functioning of people with first-episode psychosis. *J Psychiatr Res*.

- 2023;160:171-176. doi:10.1016/j.jpsychires.2023.02.014
8. Misiak B, Piotrowski P, Samochowiec J. Assessment of interrelationships between cognitive performance, symptomatic manifestation and social functioning in the acute and clinical stability phase of schizophrenia: insights from a network analysis. *BMC Psychiatry*. 2023;23(1):774. doi:10.1186/s12888-023-05289-4
  9. Kharawala S, Hastedt C, Podhorna J, Shukla H, Kappelhoff B, Harvey PD. The relationship between cognition and functioning in schizophrenia: a semi-systematic review. *Schizophr Res Cogn*. 2021;27:100217. doi:10.1016/j.scog.2021.100217
  10. Lystad JU, Falkum E, Haaland VØ, et al. Neurocognition and occupational functioning in schizophrenia spectrum disorders: the MATRICS Consensus Cognitive Battery (MCCB) and workplace assessments. *Schizophr Res*. 2016;170(1):143-149. doi:10.1016/j.schres.2015.12.002
  11. Knowles EEM, David AS, Reichenberg A. Processing speed deficits in schizophrenia: reexamining the evidence. *Am J Psychiatry*. 2010;167(7):828-835. doi:10.1176/appi.ajp.2010.09070937
  12. Prah P, Petersen I, Nazareth I, Walters K, Osborn D. National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. *Pharmacoepidemiol Drug Saf*. 2012;21(2):161-169. doi:10.1002/pds.2213
  13. Salthouse TA. The processing-speed theory of adult age differences in cognition. *Psychol Rev*. 1996;103(3):403-428. doi:10.1037/0033-295X.103.3.403
  14. Carroll JB. *Human Cognitive Abilities: A Survey of Factor-Analytic Studies*. Cambridge University Press; 1993. doi:10.1017/CBO9780511571312
  15. Gulliksen H. *Theory of Mental Tests*. 1st ed. Routledge; 2013.
  16. Estrada E, Román FJ, Abad FJ, Colom R. Separating power and speed components of standardized intelligence measures. *Intelligence*. 2017;61:159-168. doi:10.1016/j.intell.2017.02.002
  17. Wechsler D. Wechsler Adult Intelligence Scale, Third Edition (WAIS-III). The Psychological Corporation; 1997.
  18. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. *Schizophr Res*. 2004;68(2-3):283-297. doi:10.1016/j.schres.2003.09.011
  19. Cannon TD, Yu C, Addington J, et al. An individualized risk calculator for research in prodromal psychosis. *Am J Psychiatry*. 2016;173(10):980-988. doi:10.1176/appi.ajp.2016.15070890
  20. Harvey PD. Domains of cognition and their assessment. *Dialogues Clin Neurosci*. 2019;21(3):227-237. doi:10.31887/DCNS.2019.21.3/pharvey
  21. Kochunov P, Rowland LM, Fieremans E, et al. Diffusion-weighted imaging uncovers likely sources of processing-speed deficits in schizophrenia. *Proc Natl Acad Sci U S A*. 2016;113(47):13504-13509. doi:10.1073/pnas.1608246113
  22. Adhikari BM, Hong LE, Sampath H, et al. Functional network connectivity impairments and core cognitive deficits in schizophrenia. *Hum Brain Mapp*. 2019;40(16):4593-4605. doi:10.1002/hbm.24723
  23. Zou J, Yuan B, Hu M, et al. A comparative study of cognitive functions between schizophrenia and obsessive-compulsive disorder. *Heliyon*. 2023;9(3):e14330. doi:10.1016/j.heliyon.2023.e14330
  24. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. *J Clin Exp Neuropsychol*. 2009;31(7):848-859. doi:10.1080/13803390802592458
  25. Murillo-García N, Díaz-Pons A, Fernández-Cacho LM, et al. A family study on first episode of psychosis patients: exploring neuropsychological performance as an endophenotype. *Acta Psychiatr Scand*. 2022;145(4):384-396. doi:10.1111/acps.13404
  26. Rodríguez-Toscano E, López G, Mayoral M, et al. A longitudinal comparison of two neurocognitive test batteries in patients with schizophrenia and healthy volunteers: time effects on neuropsychological performance and their relation to functional outcome. *Schizophr Res*. 2020;216:347-356. doi:10.1016/j.schres.2019.11.018
  27. He Z, Deng W, Li M, et al. Aberrant intrinsic brain activity and cognitive deficit in first-episode treatment-naïve patients with schizophrenia. *Psychol Med*. 2013;43(4):769-780. doi:10.1017/S0033291712001638
  28. James A, Joyce E, Lunn D, et al. Abnormal frontostriatal connectivity in adolescent-onset schizophrenia and its relationship to cognitive functioning. *Eur Psychiatry*. 2016;35:32-38. doi:10.1016/j.eurpsy.2016.01.2426
  29. Mazhari S, Moghadas Tabrizi Y. Abnormalities of mental rotation of hands associated with speed of information processing and executive function in chronic schizophrenic patients. *Psychiatry Clin Neurosci*. 2014;68(6):410-417. doi:10.1111/pcn.12148
  30. Loewenstein DA, Czaja SJ, Bowie CR, Harvey PD. Age-associated differences in cognitive performance in older patients with schizophrenia: a comparison with healthy older adults. *Am J Geriatr Psychiatry*. 2012;20(1):29-40. doi:10.1097/JGP.0b013e31823bc08c
  31. Piotrowski P, Kotowicz K, Rymaszewska J, et al. Allostatic load index and its clinical correlates at various stages of psychosis. *Schizophr Res*. 2019;210:73-80. doi:10.1016/j.schres.2019.06.009
  32. Anhøj S, Ødegaard Nielsen M, Jensen MH, et al. Alterations of intrinsic connectivity networks in antipsychotic-naïve first-episode schizophrenia. *Schizophr Bull*. 2018;44(6):1332-1340. doi:10.1093/schbul/sbx171
  33. Nazeri A, Chakravarty MM, Felsky D, et al. Alterations of superficial white matter in schizophrenia and relationship to cognitive performance. *Neuropsychopharmacology*. 2013;38(10):1954-1962. doi:10.1038/npp.2013.93
  34. Wijtenburg SA, Wright SN, Korenic SA, et al. Altered glutamate and regional cerebral blood flow levels in schizophrenia: a <sup>1</sup>H-MRS and pCASL study. *Neuropsychopharmacology*. 2017;42(2):562-571. doi:10.1038/npp.2016.172
  35. Huang W, Chen C, Chen X, et al. Association between global visual scanning and cognitive function in schizophrenia. *Asian J Psychiatr*. 2021;56:102559. doi:10.1016/j.ajp.2021.102559
  36. Chen P, Ye E, Jin X, Zhu Y, Wang L. Association between thalamocortical functional connectivity abnormalities and cognitive deficits in schizophrenia. *Sci Rep*. 2019;9(1):2952. doi:10.1038/s41598-019-39367-z
  37. Stone WS, Cai B, Liu X, et al. Association between the duration of untreated psychosis and selective cognitive performance in community-dwelling individuals with chronic untreated schizophrenia in rural China. *JAMA Psychiatry*. 2020;77(11):1116-1126. doi:10.1001/jamapsychiatry.2020.1619
  38. Hidese S, Ota M, Matsuo J, et al. Association between the scores of the Japanese version of the Brief Assessment of Cognition in Schizophrenia and whole-brain structure in patients with chronic schizophrenia: a voxel-based morphometry and diffusion tensor imaging study. *Psychiatry Clin Neurosci*. 2017;71(12):826-835. doi:10.1111/pcn.12560
  39. Yang Y, Su Y, Wei G, et al. Association of NKAPL rs1635 with cognitive function in early-onset schizophrenia. *Front Genet*. 2022;13:941171. doi:10.3389/fgene.2022.941171
  40. Bhattacharyya K, Guha P, Ghosal M, Sadhukhan SK. Association of thought disorder with cognitive dysfunctions in schizophrenia: a cross-sectional study in a tertiary centre in Kolkata, India. *Geriatr Psychiatry*. 2013;16:137-142.
  41. Long Y, Ouyang X, Liu Z, et al. Associations among suicidal ideation, white matter integrity and cognitive deficit in first-episode schizophrenia. *Front Psychiatry*. 2018;9:391. doi:10.3389/fpsy.2018.00391
  42. Kuha A, Suvisaari J, Perälä J, et al. Associations of anhedonia and cognition in persons with schizophrenia spectrum disorders, their siblings, and controls. *J Nerv Ment Dis*. 2011;199(1):30-37. doi:10.1097/NMD.0b013e3182043a6d
  43. Galaverna FS, Morra CA, Bueno AM. Attention in patients with chronic schizophrenia: deficit in inhibitory control and positive symptoms. *Eur J Psychiatry*. 2012;26(3):185-195. doi:10.4321/S0213-61632012000300005
  44. Ferretjans R, de Souza RP, Panizzutti B, et al. Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. *Braz J Psychiatry*. 2022;44(1):26-34. doi:10.1590/1516-4446-2020-1650
  45. Wu Y, Song S, Shen Y. Characteristics of theory of mind impairment and its relationship with clinical symptoms and neurocognition in patients with schizophrenia. *BMC Psychiatry*. 2023;23(1):711. doi:10.1186/s12888-023-05224-7
  46. Mançe Çalışır Ö, Atbaşoğlu EC, Devrimci Özgüven H, Ölmez Ş. Cognitive features of high-functioning adults with autism and schizophrenia spectrum disorders. *Türk Psikiyatri Derg*. 2018;29(1):1-10.
  47. Watson AJ, Giordano A, Suckling J, et al. Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers. *Psychol Med*. 2023;53(7):2842-2851. doi:10.1017/S0033291721004815
  48. Nenadic I, Langbein K, Dietzek M, Forberg A, Smesny S, Sauer H. Cognitive function in euthymic bipolar disorder (BP I) patients with a history of

- psychotic symptoms vs. schizophrenia. *Psychiatry Res.* 2015;230(1):65-69. doi:10.1016/j.psychres.2015.08.012
49. Hou CL, Xiang YT, Wang ZL, et al. Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. *Schizophr Res.* 2016;174(1-3):71-76. doi:10.1016/j.schres.2016.04.034
50. Tuulio-Henriksson A, Perälä J, Saarni SI, et al. Cognitive functioning in severe psychiatric disorders: a general population study. *Eur Arch Psychiatry Clin Neurosci.* 2011;261(6):447-456. doi:10.1007/s00406-010-0186-y
51. Torniainen M, Suvisaari J, Partonen T, et al. Cognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristics. *J Nerv Ment Dis.* 2012;200(4):316-322. doi:10.1097/NMD.0b013e31824cb359
52. Díez A, Cieza-Borrella C, Suazo V, González-Sarmiento R, Papiol S, Molina V. Cognitive outcome and gamma noise power unrelated to neuregulin 1 and 3 variation in schizophrenia. *Ann Gen Psychiatry.* 2014;13(1):18. doi:10.1186/1744-859X-13-18
53. Rajji TK, Voineskos AN, Butters MA, et al. Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS consensus cognitive battery. *Am J Geriatr Psychiatry.* 2013;21(2):108-118. doi:10.1016/j.jagp.2012.10.011
54. Gurrera RJ, McCarley RW, Salisbury D. Cognitive task performance and symptoms contribute to personality abnormalities in first hospitalized schizophrenia. *J Psychiatry Res.* 2014;55:68-76. doi:10.1016/j.jpsychires.2014.03.022
55. Sheffield JM, Gold JM, Strauss ME, et al. Common and specific cognitive deficits in schizophrenia: relationships to function. *Cogn Affect Behav Neurosci.* 2014;14(1):161-174. doi:10.3758/s13415-013-0211-5
56. de Boer M, Spek AA, Lobbestael J. Comparing cognitive functioning in schizophrenia and autism using WAIS-III. *Res Autism Spectr Disord.* 2014;8(7):737-745. doi:10.1016/j.rasd.2014.03.001
57. Eslami Shahrbabaki M, Barfehie D, Mazhari S, Ahmadi A, Shafiee S. Comparing cognitive functions in patients with schizophrenia and methamphetamine-induced psychosis with healthy controls. *Addict Health.* 2022;14(4):239-243. doi:10.34172/ahj.2022.1143
58. Galderisi S, Davidson M, Kahn RS, et al; EUFEST group. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. *Schizophr Res.* 2009;115(2-3):104-114. doi:10.1016/j.schres.2009.09.022
59. Poznanovic ST, Markovic M, Stasevic M, Karlicic IS, Tomanic M. Cross-cultural adaptation and validation of the Serbian version of the Brief Assessment of Cognition in Schizophrenia Scale. *Int J Environ Res Public Health.* 2023;20(4):3699. doi:10.3390/ijerph20043699
60. Brébion G, Stephan-Otto C, Huerta-Ramos E, et al. Decreased processing speed might account for working memory span deficit in schizophrenia, and might mediate the associations between working memory span and clinical symptoms. *Eur Psychiatry.* 2014;29(8):473-478. doi:10.1016/j.eurpsy.2014.02.009
61. Liu Y, Guo W, Zhang Y, et al. Decreased resting-state interhemispheric functional connectivity correlated with neurocognitive deficits in drug-naïve first-episode adolescent-onset schizophrenia. *Int J Neuropsychopharmacol.* 2018;21(1):33-41. doi:10.1093/ijnp/pyx095
62. Knowles EEM, Weiser M, David AS, et al. Dedifferentiation and substitute strategy: deconstructing the processing-speed impairment in schizophrenia. *Schizophr Res.* 2012;142(1-3):129-136. doi:10.1016/j.schres.2012.08.020
63. Lin YT, Liu CM, Chiu MJ, et al. Differentiation of schizophrenia patients from healthy subjects by mismatch negativity and neuropsychological tests. *PLoS One.* 2012;7(4):e34454. doi:10.1371/journal.pone.0034454
64. Polimeni JO, Campbell DW, Gill D, Sawatzky BL, Reiss JP. Diminished humour perception in schizophrenia: relationship to social and cognitive functioning. *J Psychiatry Res.* 2010;44(7):434-440. doi:10.1016/j.jpsychires.2009.10.003
65. Okazaki K, Miura K, Matsumoto J, et al. Discrimination in the clinical diagnosis between patients with schizophrenia and healthy controls using eye movement and cognitive functions. *Psychiatry Clin Neurosci.* 2023;77(7):393-400. doi:10.1111/pcn.13553
66. Lutz O, Lizano P, Mothi SS, et al. Do neurobiological differences exist between paranoid and non-paranoid schizophrenia? Findings from the bipolar schizophrenia network on intermediate phenotypes study. *Schizophr Res.* 2020;223:96-104. doi:10.1016/j.schres.2020.02.011
67. Veselinović T, Vernalen I, Janouschek H, et al. Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. *Psychopharmacology (Berl).* 2015;232(9):1607-1617. doi:10.1007/s00213-014-3794-9
68. Batty R, Francis A, Thomas N, et al. Executive dysfunction in psychosis following traumatic brain injury (PFTBI). *J Clin Exp Neuropsychol.* 2015;37(9):917-930. doi:10.1080/13803395.2015.1068279
69. Morita K, Miura K, Fujimoto M, et al. Eye movement abnormalities and their association with cognitive impairments in schizophrenia. *Schizophr Res.* 2019;209:255-262. doi:10.1016/j.schres.2018.12.051
70. Xie YJ, Xi YB, Cui LB, et al. Functional connectivity of cerebellar dentate nucleus and cognitive impairments in patients with drug-naïve and first-episode schizophrenia. *Psychiatry Res.* 2021;300:113937. doi:10.1016/j.psychres.2021.113937
71. Gutiérrez-Rojas L, González-Domenech PJ, Junquera G, Halverson TF, Lahera G. Functioning and happiness in people with schizophrenia: analyzing the role of cognitive impairment. *Int J Environ Res Public Health.* 2021;18(14):7706. doi:10.3390/ijerph18147706
72. Demmo C, Lagerberg TV, Aminoff SR, et al. History of psychosis and previous episodes as potential explanatory factors for neurocognitive impairment in first-treatment bipolar I disorder. *Bipolar Disord.* 2016;18(2):136-147. doi:10.1111/bdi.12377
73. Wang LJ, Lin PY, Lee Y, et al. Increased serum levels of cysteine in patients with schizophrenia: a potential marker of cognitive function preservation. *Schizophr Res.* 2018;192:391-397. doi:10.1016/j.schres.2017.03.041
74. Shin YW, Krishnan G, Hetrick WP, et al. Increased temporal variability of auditory event-related potentials in schizophrenia and schizotypal personality disorder. *Schizophr Res.* 2010;124(1-3):110-118. doi:10.1016/j.schres.2010.08.008
75. Krukow P, Harciarek M, Moryłowska-Topolska J, Karakula-Juchnowicz H, Jonak K. Ineffective initiation contributes to deficient verbal and non-verbal fluency in patients with schizophrenia. *Cogn Neuropsychiatry.* 2017;22(5):391-406. doi:10.1080/13546805.2017.1356710
76. Brown EC, Hack SM, Gold JM, et al. Integrating frequency and magnitude information in decision-making in schizophrenia: an account of patient performance on the Iowa Gambling Task. *J Psychiatr Res.* 2015;66-67:16-23. doi:10.1016/j.jpsychires.2015.04.007
77. Vahia IV, Palmer BW, Depp C, et al. Is late-onset schizophrenia a subtype of schizophrenia? *Acta Psychiatr Scand.* 2010;122(5):414-426. doi:10.1111/j.1600-0447.2010.01552.x
78. McGuire J, Brüne M, Langdon R. Judgment of moral and social transgression in schizophrenia. *Compr Psychiatry.* 2017;76:160-168. doi:10.1016/j.comppsy.2017.04.008
79. Fett AJ, Velthorst E, Reichenberg A, et al. Long-term changes in cognitive functioning in individuals with psychotic disorders: findings from the Suffolk County Mental Health Project. *JAMA Psychiatry.* 2020;77(4):387-396. doi:10.1001/jamapsychiatry.2019.3993
80. Gao Y, Li M, Huang AS, et al. Lower functional connectivity of white matter during rest and working memory tasks is associated with cognitive impairments in schizophrenia. *Schizophr Res.* 2021;233:101-110. doi:10.1016/j.schres.2021.06.013
81. Almulla AF, Moustafa SR, Al-Dujaili AH, Al-Hakeim HK, Maes M. Lowered serum cesium levels in schizophrenia: association with immune-inflammatory biomarkers and cognitive impairments. *Braz J Psychiatry.* 2021;43(2):131-137. doi:10.1590/1516-4446-2020-0908
82. Andrade-González N, Sarasa M, García-López A, Leonés I, Halverson TF, Lahera G. Mentalizing errors in patients with schizophrenia who received psychosocial rehabilitation: a case-control study. *Psychiatr Q.* 2021;92(3):947-959. doi:10.1007/s11126-020-09863-x
83. Kärger C, Sartory G, Kariofillis D, Wiltfang J, Müller BW. Mismatch negativity latency and cognitive function in schizophrenia. *PLoS One.* 2014;9(4):e84536. doi:10.1371/journal.pone.0084536
84. Weickert CS, Fung SJ, Catts VS, et al. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. *Mol Psychiatry.* 2013;18(11):1185-1192. doi:10.1038/mp.2012.137
85. Daderwal MC, Sreeraj VS, Suhas S, Rao NP, Venkatasubramanian G. Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST) as a screening tool for evaluation of cognitive deficits in schizophrenia. *Psychiatry Res.* 2022;316:114731. doi:10.1016/j.psychres.2022.114731
86. Rudolph A, Liepelt R, Kaffes M, Hofmann-Shen C, Montag C, Neuhaus AH. Motor cognition in schizophrenia: control of automatic imitation and



- mapping of action context are reduced. *Schizophr Res*. 2022;240:116-124. doi:10.1016/j.schres.2021.12.024
87. Jessen F, Fingerhut N, Sprinkart AM, et al. N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. *Schizophr Bull*. 2013;39(1):197-205. doi:10.1093/schbul/sbr127
88. Eifler S, Rausch F, Schirmbeck F, et al. Neurocognitive capabilities modulate the integration of evidence in schizophrenia. *Psychiatry Res*. 2014;219(1):72-78. doi:10.1016/j.psychres.2014.04.056
89. Simonsen C, Sundet K, Vaskinn A, et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. *Schizophr Bull*. 2011;37(1):73-83. doi:10.1093/schbul/sbp034
90. Kashiwagi H, Matsumoto J, Miura K, et al. Neurocognitive features, personality traits, and social function in patients with schizophrenia with a history of violence. *J Psychiatr Res*. 2022;147:50-58. doi:10.1016/j.jpsychires.2022.01.012
91. Ceylan D, Akdede BB, Bora E, et al. Neurocognitive functioning during symptomatic states and remission in bipolar disorder and schizophrenia: a comparative study. *Psychiatry Res*. 2020;292:113292. doi:10.1016/j.psychres.2020.113292
92. Kuswanto CN, Sum MY, Sim K. Neurocognitive functioning in schizophrenia and bipolar disorder: clarifying concepts of diagnostic dichotomy vs. continuum. *Front Psychiatry*. 2013;4:162. doi:10.3389/fpsy.2013.00162
93. Shen C, Popescu FC, Hahn E, Ta TTM, Dettling M, Neuhaus AH. Neurocognitive pattern analysis reveals classificatory hierarchy of attention deficits in schizophrenia. *Schizophr Bull*. 2014;40(4):878-885. doi:10.1093/schbul/sbt107
94. Kravriti E, Morgan K, Fearon P, et al. Neuropsychological functioning in first-episode schizophrenia. *Br J Psychiatry*. 2009;195(4):336-345. doi:10.1192/bjp.bp.108.055590
95. Caletti E, Paoli RA, Fiorentini A, et al. Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data. *Front Hum Neurosci*. 2013;7:661. doi:10.3389/fnhum.2013.00661
96. Molina V, Cortés B, Pérez J, et al. No association between prepulse inhibition of the startle reflex and neuropsychological deficit in chronic schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 2010;260(8):609-615. doi:10.1007/s00406-010-0102-5
97. Perez MM, Tercero BA, Penn DL, Pinkham AE, Harvey PD. Overconfidence in social cognitive decision making: Correlations with social cognitive and neurocognitive performance in participants with schizophrenia and healthy individuals. *Schizophr Res*. 2020;224:51-57. doi:10.1016/j.schres.2020.10.005
98. Xia L, Yuan L, Du XD, et al. P50 inhibition deficit in patients with chronic schizophrenia: relationship with cognitive impairment of MATRICS consensus cognitive battery. *Schizophr Res*. 2020;215:105-112. doi:10.1016/j.schres.2019.11.012
99. Li S, Yu B, Wang D, et al. P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia. *J Affect Disord*. 2023;324:153-161. doi:10.1016/j.jad.2022.12.143
100. Molina V, Lubeiro A, Blanco J, et al. Parkinsonism is associated to fronto-caudate disconnectivity and cognition in schizophrenia. *Psychiatry Res Neuroimaging*. 2018;277:1-6. doi:10.1016/j.pscychresns.2018.04.009
101. Fujino H, Sumiyoshi C, Sumiyoshi T, et al. Performance on the Wechsler Adult Intelligence Scale-III in Japanese patients with schizophrenia. *Psychiatry Clin Neurosci*. 2014;68(7):534-541. doi:10.1111/pcn.12165
102. Wright SN, Hong LE, Winkler AM, et al. Perfusion shift from white to gray matter may account for processing speed deficits in schizophrenia. *Hum Brain Mapp*. 2015;36(10):3793-3804. doi:10.1002/hbm.22878
103. Akiyama K, Saito S, Saito A, et al. Predictive value of premorbid IQ, negative symptoms, and age for cognitive and social functions in Japanese patients with schizophrenia: a study using the Japanese version of the Brief Assessment of Cognition in Schizophrenia. *Psychiatry Res*. 2016;246:663-671. doi:10.1016/j.psychres.2016.10.070
104. Karbasforoushan H, Duffy B, Blackford JU, Woodward ND. Processing speed impairment in schizophrenia is mediated by white matter integrity. *Psychol Med*. 2015;45(1):109-120. doi:10.1017/S003329714001111
105. Lazarević LB, Knežević G, Mitić M, Jočić DD. Psychometric properties of the Serbian version of the Wechsler adult intelligence scale (WAIS-IV). *Psihologija*. 2018;51(3):333-349. doi:10.2298/PSI170010010L
106. Liao J, Yan H, Liu Q, et al. Reduced paralimbic system gray matter volume in schizophrenia: correlations with clinical variables, symptomatology and cognitive function. *J Psychiatr Res*. 2015;65:80-86. doi:10.1016/j.jpsychires.2015.04.008
107. Ochoa S, Haro JM, Huerta-Ramos E, et al. Relation between jumping to conclusions and cognitive functioning in people with schizophrenia in contrast with healthy participants. *Schizophr Res*. 2014;159(1):211-217. doi:10.1016/j.schres.2014.07.026
108. Brébion G, Bressan RA, David AS, Pilowsky LS. Role of processing speed and premorbid IQ on visual recognition in patients with schizophrenia. *J Clin Exp Neuropsychol*. 2009;31(3):302-311. doi:10.1080/13803390802108362
109. Koshiyama D, Fukunaga M, Okada N, et al. Role of subcortical structures on cognitive and social function in schizophrenia. *Sci Rep*. 2018;8(1):1183. doi:10.1038/s41598-017-18950-2
110. Lundin NB, Todd PM, Jones MN, Avery JE, O'Donnell BF, Hetrick WP. Semantic search in psychosis: modeling local exploitation and global exploration. *Schizophr Bull Open*. 2020;1(1):sgaa011. doi:10.1093/schizbullopen/sgaa011
111. Huang YC, Lin PY, Lee Y, et al. Serum levels of  $\beta$ -hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study. *Neuropsychiatr Dis Treat*. 2018;14:799-808. doi:10.2147/NDT.S157055
112. Moore L, Kyaw M, Vercammen A, et al. Serum testosterone levels are related to cognitive function in men with schizophrenia. *Psychoneuroendocrinology*. 2013;38(9):1717-1728. doi:10.1016/j.psyneuen.2013.02.007
113. Mu L, Liang J, Wang H, Chen D, Xiu M, Zhang XY. Sex differences in association between clinical correlates and cognitive impairment in patients with chronic schizophrenia. *J Psychiatr Res*. 2020;131:194-202. doi:10.1016/j.jpsychires.2020.09.003
114. Zhao N, Wang XH, Kang CY, et al. Sex differences in association between cognitive impairment and clinical correlates in Chinese patients with first-episode drug-naïve schizophrenia. *Ann Gen Psychiatry*. 2021;20(1):26. doi:10.1186/s12991-021-00347-1
115. Torniainen M, Suvisaari J, Partonen T, et al. Sex differences in cognition among persons with schizophrenia and healthy first-degree relatives. *Psychiatry Res*. 2011;188(1):7-12. doi:10.1016/j.psychres.2010.11.009
116. Vaskinn A, Sundet K, Simonsen C, Hellvin T, Melle I, Andreassen OA. Sex differences in neuropsychological performance and social functioning in schizophrenia and bipolar disorder. *Neuropsychology*. 2011;25(4):499-510. doi:10.1037/a0022677
117. Ruiz-Toca A, Fernández-Aragón C, Madrigal A, Halverson T, Rodríguez-Jiménez R, Lahera G. Social cognition mediates the impact of processing speed and sustained attention on global functioning in schizophrenia. *Psicothema*. 2023;35(1):87-97. doi:10.7334/psicothema2022.8
118. de Jong S, van Donkersgoed R, Renard S, et al. Social-cognitive risk factors for violence in psychosis: a discriminant function analysis. *Psychiatry Res*. 2018;265:93-99. doi:10.1016/j.psychres.2018.04.048
119. Segarra N, Bernardo M, Gutierrez F, et al. Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls. *Eur Psychiatry*. 2011;26(2):69-73. doi:10.1016/j.eurpsy.2009.11.001
120. Peng S, Liang C, Deng S, Fu Y. Study on the clinical correlation between the expression of serum TNF- $\alpha$  and iNOS as well as cognitive impairment and disease burden in patients with schizophrenia. *Pak J Med Sci*. 2022;38(7):1838-1843. doi:10.12669/pjms.38.7.5326
121. Hartmann-Riemer MN, Hager OM, Kirschner M, et al. The association of neurocognitive impairment with diminished expression and apathy in schizophrenia. *Schizophr Res*. 2015;169(1-3):427-432. doi:10.1016/j.schres.2015.10.032
122. Zhang L, Zheng H, Wu R, Kosten TR, Zhang XY, Zhao J. The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. *Schizophr Res*. 2019;212:92-98. doi:10.1016/j.schres.2019.08.005
123. Kuswanto CN, Sum MY, Qiu A, Sitoh YY, Liu J, Sim K. The impact of genome wide supported microRNA-137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia. *Am J Med Genet B Neuropsychiatr Genet*. 2015;168B(5):317-326. doi:10.1002/ajmg.b.32314
124. Andersen R, Fagerlund B, Rasmussen H, et al. The influence of impaired processing speed on cognition in first-episode antipsychotic-naïve schizophrenic patients. *Eur Psychiatry*. 2013;28(6):332-339. doi:10.1016/j.eurpsy.2012.06.003

125. Leeson VC, Barnes TRE, Harrison M, et al. The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome. *Schizophr Bull*. 2010;36(2):400-409. doi:10.1093/schbul/sbn100
126. Veselinović T, Vernaleken I, Janouschek H, et al. The role of striatal dopamine D<sub>2/3</sub> receptors in cognitive performance in drug-free patients with schizophrenia. *Psychopharmacology (Berl)*. 2018;235(8):2221-2232. doi:10.1007/s00213-018-4916-6
127. Anselmetti S, Bechi M, Bosia M, et al. 'Theory' of mind impairment in patients affected by schizophrenia and in their parents. *Schizophr Res*. 2009;115(2-3):278-285. doi:10.1016/j.schres.2009.09.018
128. Lindgren M, Torniainen-Holm M, Heiskanen I, et al. Theory of mind in a first-episode psychosis population using the Hinting Task. *Schizophr Res*. 2018;263:185-192. doi:10.1016/j.psychres.2018.03.014
129. Velthorst E, Levine SZ, Henquet C, et al. To cut a short test even shorter: reliability and validity of a brief assessment of intellectual ability in schizophrenia—a control-case family study. *Cogn Neuropsychiatry*. 2013;18(6):574-593. doi:10.1080/13546805.2012.731390
130. Seitz J, Zuo JX, Lyall AE, et al. Tractography analysis of 5 white matter bundles and their clinical and cognitive correlates in early-course schizophrenia. *Schizophr Bull*. 2016;42(3):762-771. doi:10.1093/schbul/sbv171
131. Yu Z-M, Zhao Y, Zhan J-Q, et al. Treatment responses of cognitive function and plasma asymmetric dimethylarginine to atypical antipsychotic in patients with schizophrenia. *Front Psychiatry*. 2019;9. doi:10.3389/fpsy.2018.00733
132. Wang LJ, Lin PY, Lee Y, et al. Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia. *Neuropsychiatr Dis Treat*. 2016;12:2819-2826. doi:10.2147/NDT.S118110
133. Brébion G, Stephan-Otto C, Ochoa S, Nieto L, Contel M, Usall J. Verbal fluency in male and female schizophrenia patients: different patterns of association with processing speed, working memory span, and clinical symptoms. *Neuropsychology*. 2018;32(1):65-76. doi:10.1037/neu0000394
134. Ojeda N, Sánchez P, Peña J, et al. Verbal fluency in schizophrenia: does cognitive performance reflect the same underlying mechanisms in patients and healthy controls? *J Nerv Ment Dis*. 2010;198(4):286-291. doi:10.1097/NMD.0b013e3181d61748
135. Michel NM, Goldberg JO, Heinrichs RW, Miles AA, Ammari N, McDermid Vaz S. WAIS-IV profile of cognition in schizophrenia. *Assessment*. 2013;20(4):462-473. doi:10.1177/1073191113478153
136. Yamada S, Takahashi S, Ohoshi Y, et al. Widespread white matter microstructural abnormalities and cognitive impairment in schizophrenia, bipolar disorder, and major depressive disorder: tract-based spatial statistics study. *Psychiatry Res Neuroimaging*. 2020;298:111045. doi:10.1016/j.pscychres.2020.111045
137. Brébion G, David AS, Jones HM, Pilowsky LS. Working memory span and motor and cognitive speed in schizophrenia. *Cogn Behav Neurol*. 2009;22(2):101-108. doi:10.1097/WNN.0b013e3181a722a0
138. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. *Clin Neuropsychol*. 1991;5(2):125-142. doi:10.1080/13854049108403297
139. Elwood RW. The California Verbal Learning Test: psychometric characteristics and clinical application. *Neuropsychol Rev*. 1995;5(3):173-201. doi:10.1007/BF02214761
140. Rey A. L'examen Clinique. In: *Psychologie*. [The Clinical Examination in Psychology.] Presses Universitaires De France; 1958:222.
141. R Core Team. R: a language and environment for statistical computing. 2022. <https://www.R-project.org/>
142. Viechtbauer W. Conducting meta-analyses in R with the metafor Package. *J Stat Softw*. 2010;36(3). doi:10.18637/jss.v036.i03
143. Hedges LV, Olkin I. *Statistical Methods for Meta-Analysis*. Elsevier Science; 2014.
144. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I<sup>2</sup> index? *Psychol Methods*. 2006;11(2):193-206. doi:10.1037/1082-989X.11.2.193
145. Lin L. Comparison of four heterogeneity measures for meta-analysis. *J Eval Clin Pract*. 2020;26(1):376-384. doi:10.1111/jep.13159
146. Orwin RGA. Fail-safe N for effect size in meta-analysis. *J Educ Stat*. 1983;8(2):157-159. doi:10.2307/1164923
147. Henry JD, Crawford JR. A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits. *Cogn Neuropsychiatry*. 2005;10(1):1-33. doi:10.1080/13546800344000309
148. Sullivan GM, Feinn R. Using effect size—or why the P value is not enough. *J Grad Med Educ*. 2012;4(3):279-282. doi:10.4300/JGME-D-12-00156.1
149. Sheffield JM, Barch DM. Cognition and resting-state functional connectivity in schizophrenia. *Neurosci Biobehav Rev*. 2016;61:108-120. doi:10.1016/j.neubiorev.2015.12.007
150. Ebaid D, Crewther SG, MacCalman K, Brown A, Crewther DP. Cognitive processing speed across the lifespan: beyond the influence of motor speed. *Front Aging Neurosci*. 2017;9:62. doi:10.3389/fnagi.2017.00062
151. O'Shea DM, Maynard T, Tremont G. DNA methylation "GrimAge" acceleration mediates sex/gender differences in verbal memory and processing speed: findings from the Health and Retirement study. *J Gerontol A Bio Sci Med Sci*. 2022;77(12):2404-2412.
152. Roivainen E, Suokas F, Saari A. An examination of factors that may contribute to gender differences in psychomotor processing speed. *BMC Psychol*. 2021;9(1):190. doi:10.1186/s40359-021-00698-0
153. Tsai PC, McDowd J, Tang TC, Su CY. Processing speed mediates gender differences in memory in schizophrenia. *Clin Neuropsychol*. 2012;26(4):626-640. doi:10.1080/13854046.2012.678887
154. Kurebayashi Y, Otaki J. Neurocognitive differences between inpatients and outpatients with symptomatically nonremitted schizophrenia: a cross-sectional study. *Perspect Psychiatr Care*. 2018;54(4):501-506. doi:10.1111/ppc.12257
155. Barch DM, Sheffield JM. Cognitive impairments in psychotic disorders: common mechanisms and measurement. *World Psychiatry*. 2014;13(3):224-232. doi:10.1002/wps.20145
156. Sherman EMS, Brooks BL, Iverson GL, Slick DJ, Strauss E. Reliability and Validity in Neuropsychology. In: Schoenberg MR, Scott JG, eds. *The Little Black Book of Neuropsychology*. Springer US; 2011:873-892. doi:10.1007/978-0-387-76978-3\_30